

**OTHER TRANSACTION AGREEMENT (OTA)**

OTHER TRANSACTION FOR ADVANCED RESEARCH (OTAR)

BETWEEN

**Regeneron Pharmaceuticals, Inc.**  
**777 Old Saw Mill River Road**  
**Tarrytown, New York 10591-6717**

AND

**THE UNITED STATES OF AMERICA**  
**DEPARTMENT OF HEALTH AND HUMAN SERVICES**  
**ASSISTANT SECRETARY FOR PREPAREDNESS AND RESPONSE**  
200 C Street, S.W.  
WASHINGTON, DC 20515

CONCERNING

(b)(4)

Date: January 31, 2020

PR No. (b)(4)

Total Amount of the Agreement (b)(4)

Total Estimated Government Funding of the Agreement (b)(4)

Total Estimated Recipient Funding of the Agreement (b)(4)

Funds Obligated: (b)(4)

Period of Performance: September 30, 2017 through June 30, 2022 (Changed)

Authority: Section 319L(c) (4) (B) and/or 319L(c) (4) (D) of the Pandemic and All-Hazards Preparedness Act, P.L. 109-417

Line of Accounting and Appropriation

(b)(4)

Line of Accounting and Appropriation

(b)(4)

Line of Accounting and Appropriation

(b)(4)

Line of Accounting and Appropriation

(b)(4)

Line of Accounting and Appropriation

(b)(4)

(b)(4)

Line of Accounting and Appropriation: (b)(4)

(b)(4)

Line of Accounting and Appropriation: (b)(4)

(b)(4)

Line of Accounting and Appropriation: (b)(4)

(b)(4)

Line of Accounting and Appropriation: (b)(4)

(b)(4)

**PURPOSE:** The purpose of this modification is to (1) (b)(4) and (2) Replace Attachment 1: SOW revision dated January 31, 2020.

Beginning with the effective date of this modification, the Government and Other Transaction Agreement holder mutually agree as follows:

- 1. Agreement No.: HHSO100201700020C Line Items and corresponding values:

Funding for this OTA is revised as follows:

Line Item	Recipient Cost-Share	Government Cost-Share	Total Estimated Cost	Total Government Funds Obligated to Date
(b)(4)				

Note:

- (i) (b)(4)
- (ii) External (Subrecipient or Affiliates) Expenses. External expenses will be billed based on actual third-party charges submitted to Regeneron.
- (iii) (b)(4)

(b)(4)

(iv)

2. Attached are the following documents which support the modified (b)(4)

1) Delete and replace Attachment 1 – Revised Statement of Work (SOW) dated January 31, 2020 (18 pages)

All other terms and conditions remain the same.

*FOR THE UNITED STATES OF AMERICA  
OFFICE OF ACQUISITION MANAGEMENT,  
CONTRACTS & GRANTS SECRETARY  
FOR PREPAREDNESS AND RESPONSE*

(b)(6)

FOR Regeneron Pharmaceuticals, Inc.

(b)(6)

END OF MODIFICATION (b)(4) TO HHSO100201700020C

(b)(4)

(b)(4)

Total Amount of the Agreement:

(b)(4)

Total Estimated Government Funding of the Agreement:

(b)(4)

Total Estimated Recipient Funding of the Agreement:

(b)(4)

Funds Obligated

(b)(4)

Period of Performance: September 30, 2017 through March 31, 2026 (Changed)

Authority: Section 319L(c) (4) (B) and/or 319L(c) (4) (D) of the Pandemic and All-Hazards Preparedness Act, P.L. 109-417

(b)(4)

(b)(4)

(b)(4)




Beginning with the effective date of this modification, the Government and Other Transaction Agreement holder mutually agree as follows:

- 1. Agreement No.:  
HHSO100201700020C Line Items and corresponding values:

Funding for this OTA is revised as follows:

<b>Line Item</b>	<b>Recipient</b>	<b>Government</b>	<b>Total Estimated</b>	<b>Total</b>
	<i>Cost Share</i>	<i>Cost Share</i>	<b>Cost</b>	<b>Government</b>
				<b>Funds</b>
				<b>Obligated to</b>
				<b>Date</b>



**Note:**

(i) (b)(4)

(ii) External (Subrecipient or Affiliates) Expenses. External expenses will be billed based on actual third-party charges submitted to Regeneron.

(iii) (b)(4)

(iv)

2. Under Article II PERIOD OF PERFORMANCE, delete and replace as follows:

Line Item	Description of Services	Period of Performance
(b)(4)		

3. Under **ATTACHMENT 2, REPORTING REQUIREMENTS**, add three deliverables as follows:

**Unless otherwise stated, each deliverable in the table below shall be provided as one (1) electronic copy to the COR, CS, and CO.**

**In addition to or in replacement of electronic copies, the CO may direct the Contractor to submit the below deliverables via BARDA Digital Resources Portal in machine readable format.**

CDRL#	Deliverable	Deliverable Description	Reporting Procedures and Due Dates
01.6	(b)(4)	Upon request of the Government relating to COVID-19, the Contractor shall participate in regular updates with the project staff (via teleconference or email). Contractor will respond in a timely fashion (if reasonable and practicable under the circumstances, within the same day as the request).	<p>No agenda will be required for the meeting</p> <p>No meeting minutes are required</p>

		(b)(4)	Contractor will provide updates verbally, in bulleted emails or other mutually agreed formats
		The updates will address the content reasonably requested by BARDA and in the possession of, and reasonably accessible to, Regeneron, including key cost, schedule and technical	
		(b)(4)	
		provide the update in both confidential and non-confidential formats.	
		Updates may occur on weekdays, excluding federal holidays. Upon request of the Government, check-ins may also occur on weekends and on federal holidays, provided at least 24 hours' notice.	
02.8	Product Development Source Material and Manufacturing Report for COVID-19 Programs	(b)(4) The Contractor shall submit a spreadsheet regarding critical project materials. The form and content of the spreadsheet will be similar to past updates	<ul style="list-style-type: none"> <li>Contractor will submit Product Development Source Material Report</li> </ul> <p>Within 30 business days of contract award</p> <p>Within 30 business days of substantive changes are made to sources and/or materials</p> <p>The Government will provide written comments to the Product Development Source Material and Manufacturing Report within 15 business days after the submission</p> <p>If corrective action is recommended, Contractor will respond to such concerns in writing</p>
		(b)(4)	

4. Attached are the following revised documents:

- 1) Delete and replace Attachment 1 – Revised Statement of Work (SOW) dated March 20, 2020 18 pages).
- 2) Delete and replace Attachment 6 - Requisition Table

All other terms and conditions remain the same.

FOR THE UNITED STATES OF AMERICA  
OFFICE OF ACQUISITION MANAGEMENT,  
CONTRACTS & GRANTS SECRETARY

(b)(6)



FOR Regeneron Pharmaceuticals, Inc.

(b)(6)



END OF MODIFICATION No. 0006 TO HHSO100201700020C